# A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

> **NCT03531892** · PHASE3 · COMPLETED · sponsor: **EA Pharma Co., Ltd.** · enrollment: 198 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** AJM300
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03531892
- **Lead sponsor:** EA Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-06
- **Primary completion:** 2020-11-09
- **Final completion:** 2023-03-28
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2023-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531892, "A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03531892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*